Orbital inflammatory disease management

References

• Montagnese F, Wenninger S, Schoser B. “Orbiting around” the orbital myositis: clinical features, differential diagnosis and therapy. J Neurol. 2016;263(4):631–640.
   PubMed Web of Science ®Google Scholar
• Schoser BG. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review. Clin Ophthalmol. 2007;1(1):37–42.
   PubMedGoogle Scholar
• Lacey B, Chang W, Rootman J. Nonthyroid causes of extraocular muscle disease. Surv Ophthalmol. 1999;44(3):187–213.
   PubMed Web of Science ®Google Scholar
• Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology. 1997;104(3):402–408.
   PubMed Web of Science ®Google Scholar
• Yan J, Wu P. Idiopathic orbital myositis. J Craniofac Surg. 2014;25(3):884–887.
   PubMed Web of Science ®Google Scholar
• Rootman J. Diseases of the orbit: a multidisciplinary approach. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.
   Google Scholar
• Garcia-Pous M, Hernandez-Garfella ML, Diaz-Llopis M. Treatment of chronic orbital myositis with daclizumab. Can J Ophthalmol. 2007;42(1):156–157.
   PubMed Web of Science ®Google Scholar
• Harris GJ. Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy: the 2005 ASOPRS foundation lecture. Ophthal Plast Reconstr Surg. 2006;22(2):79–86.
   PubMed Web of Science ®Google Scholar
• Hernandez-Garfella ML, Gracia-Garcia A, Cervera-Taulet E, et al. Adalimumab for recurrent orbital myositis in Crohn’s disease: report of a case with a 3-year follow-up. J Crohns Colitis. 2011;5(3):265–266.
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. 2006;34(4):365–374.
   PubMed Web of Science ®Google Scholar
• Sahlin S, Lignell B, Williams M, et al. Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol. 2009;87(8):906–908.
   PubMed Web of Science ®Google Scholar
• Bijlsma WR, Van ‘T Hullenaar FC, Mourits MP, et al. Evaluation of classification systems for nonspecific idiopathic orbital inflammation. Orbit. 2012;31(4):238–245.
   PubMedGoogle Scholar
• Mombaerts I. The many facets of dacryoadenitis. Curr Opin Ophthalmol. 2015;26(5):399–407.
   PubMed Web of Science ®Google Scholar
• Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121(4):491–499.
   PubMedGoogle Scholar
• Andrew NH, Kearney D, Sladden N, et al. Idiopathic Dacryoadenitis: clinical features, histopathology, and treatment outcomes. Am J Ophthalmol. 2016;163:148–153.
   PubMed Web of Science ®Google Scholar
• Mombaerts I, Schlingemann RO, Goldschmeding R, et al. Are systemic corticosteroids useful in the management of orbital pseudotumors? Ophthalmology. 1996;103(3):521–528.
   PubMed Web of Science ®Google Scholar
• Swamy BN, McCluskey P, Nemet A, et al. Idiopathic orbital inflammatory syndrome: clinical features and treatment outcomes. Br J Ophthalmol. 2007;91(12):1667–1670.
   PubMed Web of Science ®Google Scholar
• Mombaerts I, Cameron JD, Chanlalit W, et al. Surgical debulking for idiopathic dacryoadenitis: a diagnosis and a cure. Ophthalmology. 2014;121(2):603–609.
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Prabhakaran VC, Davis G, et al. Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation. Arch Ophthalmol. 2007;125(12):1647–1651.
   PubMedGoogle Scholar
• Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539–551.
   PubMed Web of Science ®Google Scholar
• Andrew N, Kearney D, Selva D. IgG4-related orbital disease: a meta-analysis and review. Acta Ophthalmol. 2013;91(8):694–700.
   PubMed Web of Science ®Google Scholar
• Kubota T, Moritani S. Orbital IgG4-related disease: clinical features and diagnosis. ISRN Rheumatol. 2012;2012:412896.
   PubMedGoogle Scholar
• Lindfield D, Attfield K, McElvanney A. Systemic immunoglobulin G4 (IgG4) disease and idiopathic orbital inflammation; removing ‘idiopathic’ from the nomenclature? Eye (Lond). 2012;26(5):623–629.
   PubMed Web of Science ®Google Scholar
• Plaza JA, Garrity JA, Dogan A, et al. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease. Arch Ophthalmol. 2011;129(4):421–428.
   PubMedGoogle Scholar
• Wu A, Andrew NH, McNab AA, et al. IgG4-related ophthalmic disease: pooling of published cases and literature review. Curr Allergy Asthma Rep. 2015;15(6):27.
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum. 2014;43(6):806–817.
   PubMed Web of Science ®Google Scholar
• Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015;29(1):122–128.
   PubMed Web of Science ®Google Scholar
• Rootman J, McCarthy M, White V, et al. Idiopathic sclerosing inflammation of the orbit. A distinct clinicopathologic entity. Ophthalmology. 1994;101(3):570–584.
   PubMed Web of Science ®Google Scholar
• Garner A. Pathology of ‘pseudotumours’ of the orbit: a review. J Clin Pathol. 1973;26(9):639–648.
   PubMed Web of Science ®Google Scholar
• Chen YM, Hu FR, Liao SL. Idiopathic sclerosing orbital inflammation–a case series study. Ophthalmologica. 2010;224(1):55–58.
   PubMed Web of Science ®Google Scholar
• Hsuan JD, Selva D, McNab AA, et al. Idiopathic sclerosing orbital inflammation. Arch Ophthalmol. 2006;124(9):1244–1250.
   PubMedGoogle Scholar
• Pemberton JD, Fay A. Idiopathic sclerosing orbital inflammation: a review of demographics, clinical presentation, imaging, pathology, treatment, and outcome. Ophthal Plast Reconstr Surg. 2012;28(1):79–83.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim YS, Yang SW, et al. Radiotherapy with or without surgery for patients with idiopathic sclerosing orbital inflammation refractory or intolerant to steroid therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):52–58.
   PubMed Web of Science ®Google Scholar
• On AV, Hirschbein MJ, Williams HJ, et al. CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease. Ophthal Plast Reconstr Surg. 2006;22(5):395–397.
   PubMed Web of Science ®Google Scholar
• Patel AK, Hoch S, Shindler KS. Mycophenolate mofetil treatment of steroid-resistant idiopathic sclerosing orbital inflammation. Clin Experiment Ophthalmol. 2011;39(9):912–913.
   PubMed Web of Science ®Google Scholar
• Sivak-Callcott JA, Rootman J, Rasmussen SL, et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol. 2006;90(5):602–608.
   PubMed Web of Science ®Google Scholar
• Miszkiel KA, Sohaib SA, Rose GE, et al. Radiological and clinicopathological features of orbital xanthogranuloma. Br J Ophthalmol. 2000;84(3):251–258.
   PubMed Web of Science ®Google Scholar
• Hammond MD, Niemi EW, Ward TP, et al. Adult orbital xanthogranuloma with associated adult-onset asthma. Ophthal Plast Reconstr Surg. 2004;20(4):329–332.
   PubMed Web of Science ®Google Scholar
• Elner VM, Mintz R, Demirci H, et al. Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Trans Am Ophthalmol Soc. 2005;103:69–73. discussion −4.
   PubMedGoogle Scholar
• Karcioglu ZA, Sharara N, Boles TL, et al. Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg. 2003;19(5):372–381.
   PubMed Web of Science ®Google Scholar
• Ebrahimi KB, Miller NR, Sassani JW, et al. Failure of radiation therapy in orbital xanthogranuloma. Ophthal Plast Reconstr Surg. 2010;26(4):259–264.
   PubMed Web of Science ®Google Scholar
• Jakobiec FA, Mills MD, Hidayat AA, et al. Periocular xanthogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc. 1993;91:99–125; discussion −9.
   PubMedGoogle Scholar
• Ugurlu S, Bartley GB, Gibson LE. Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol. 2000;129(5):651–657.
   PubMed Web of Science ®Google Scholar
• Sanz-Marco E, Espana E, Lopez-Prats MJ, et al. [Necrobiotic xanthogranuloma. differential diagnosis, treatment and systemic involvement. case report]. Arch Soc Esp Oftalmol. 2014;89(5):186–189.
   PubMedGoogle Scholar
• Rayner SA, Duncombe AS, Keefe M, et al. Necrobiotic xanthogranuloma occurring in an eyelid scar. Orbit. 2008;27(3):191–194.
   PubMedGoogle Scholar
• Guo J, Wang J. Adult orbital xanthogranulomatous disease: review of the literature. Arch Pathol Lab Med. 2009;133(12):1994–1997.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Tomelleri A, Cavalli G, et al. Erdheim-Chester disease. Eur J Intern Med. 2015;26(4):223–229.
   PubMed Web of Science ®Google Scholar
• Kerstetter J, Wang J. Adult orbital Xanthogranulomatous disease: a review with emphasis on etiology, systemic associations, diagnostic tools, and treatment. Dermatol Clin. 2015;33(3):457–463.
   PubMed Web of Science ®Google Scholar
• Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157–169.
   PubMed Web of Science ®Google Scholar
• Rozenberg I, Wechsler J, Koenig F, et al. Erdheim-Chester disease presenting as malignant exophthalmos. Br J Radiol. 1986;59(698):173–177.
   PubMed Web of Science ®Google Scholar
• Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88(6):844–847.
   PubMed Web of Science ®Google Scholar
• Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica. 2006;91(8):1121–1125.
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992–2994.
   PubMed Web of Science ®Google Scholar
• Esmaeli B, Ahmadi A, Tang R, et al. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001;132(6):945–947.
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–2782.
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54(10):3330–3336.
   PubMed Web of Science ®Google Scholar
• Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30(28):e286–90.
   PubMed Web of Science ®Google Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–2703.
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411–418.
   PubMed Web of Science ®Google Scholar
• Grumbine FL, Aderman C, Vagefi MR, et al. Orbital MRI pre- and post-vemurafenib therapy for Erdheim-Chester disease. Ophthal Plast Reconstr Surg. 2015;31(6):e169.
   PubMed Web of Science ®Google Scholar
• Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007;147(9):611–619.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum. 1998;41(9):1521–1537.
   PubMed Web of Science ®Google Scholar
• Woo TL, Francis IC, Wilcsek GA, et al. Australasian orbital and adnexal Wegener’s granulomatosis. Ophthalmology. 2001;108(9):1535–1543.
   PubMed Web of Science ®Google Scholar
• Perry SR, Rootman J, White VA. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology. 1997;104(4):683–694.
   PubMed Web of Science ®Google Scholar
• Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2(5091):265–270.
   PubMed Web of Science ®Google Scholar
• Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener’s granulomatosis. Ann Intern Med. 1967;67(2):393–398.
   PubMed Web of Science ®Google Scholar
• Santiago YM, Wegener’s FA. granulomatosis of the orbit: a review of clinical features and updates in diagnosis and treatment. Semin Ophthalmol. 2011;26(4–5):349–355.
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Guillevin L. Treatment of granulomatosis with polyangiitis (Wegener’s). Expert Rev Clin Immunol. 2015;11(3):339–348.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76–85.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–498.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35(11):1322–1329.
   PubMed Web of Science ®Google Scholar
• Joy MS, Hogan SL, Jennette JC, et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant. 2005;20(12):2725–2732.
   PubMed Web of Science ®Google Scholar
• White ES, Lynch JP. Pharmacological therapy for Wegener’s granulomatosis. Drugs. 2006;66(9):1209–1228.
   PubMed Web of Science ®Google Scholar
• Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003;14(2):440–447.
   PubMed Web of Science ®Google Scholar
• Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis. Ann Rheum Dis. 2009;68(7):1125–1130.
   PubMed Web of Science ®Google Scholar
• Popa ER, Stegeman CA, Bos NA, et al. Differential B- and T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol. 1999;103(5 Pt 1):885–894.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65(7):853–858.
   PubMed Web of Science ®Google Scholar
• Omdal R, Wildhagen K, Hansen T, et al. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005;34(3):229–232.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–1547.
   PubMed Web of Science ®Google Scholar
• Martinez Del Pero M, Chaudhry A, Jones RB, et al. B-cell depletion with rituximab for refractory head and neck Wegener’s granulomatosis: a cohort study. Clin Otolaryngol. 2009;34(4):328–335.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis. 2008;67(9):1343–1346.
   PubMed Web of Science ®Google Scholar
• Wegener’s Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352(4):351–361.
   PubMed Web of Science ®Google Scholar
• Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther. 2015;9:333–347.
   PubMed Web of Science ®Google Scholar
• Bader L, Koldingsnes W, Nossent J. B-lymphocyte activating factor levels are increased in patients with Wegener’s granulomatosis and inversely correlated with ANCA titer. Clin Rheumatol. 2010;29(9):1031–1035.
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in serum of patients with Wegener’s granulomatosis. J Autoimmun. 2005;25(4):298–302.
   PubMed Web of Science ®Google Scholar
• Holden NJ, Williams JM, Morgan MD, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis. 2011;70(12):2229–2233.
   PubMed Web of Science ®Google Scholar
• Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010;185(7):4128–4136.
   PubMed Web of Science ®Google Scholar
• Hardwig PW, Bartley GB, Garrity JA. Surgical management of nasolacrimal duct obstruction in patients with Wegener’s granulomatosis. Ophthalmology. 1992;99(1):133–139.
   PubMed Web of Science ®Google Scholar
• Kwan AS, Rose GE. Lacrimal drainage surgery in Wegener’s granulomatosis. Br J Ophthalmol. 2000;84(3):329–331.
   PubMed Web of Science ®Google Scholar
• Perumal B, Black EH, Levin F, et al. Non-infectious orbital vasculitides. Eye (Lond). 2012;26(5):630–639.
   PubMed Web of Science ®Google Scholar
• Eleftheriou D, Dillon MJ, Tullus K, et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum. 2013;65(9):2476–2485.
   PubMed Web of Science ®Google Scholar
• Lightfoot RW Jr., Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088–1093.
   PubMed Web of Science ®Google Scholar
• Hutchinson CH. Polyarteritis nodosa presenting as posterior ischaemic optic neuropathy. J R Soc Med. 1984;77(12):1043–1046.
   PubMed Web of Science ®Google Scholar
• Ishida K, Yokota T, Wada Y, et al. Unilateral facial swelling and exophthalmos in a patient with polyarteritis nodosa. Intern Med. 1992;31(4):500–503.
   PubMed Web of Science ®Google Scholar
• Koike R, Yamada M, Matsunaga T, et al. Polyarteritis nodosa (PN) complicated with unilateral exophthalmos. Intern Med. 1993;32(3):232–236.
   PubMed Web of Science ®Google Scholar
• Vanwien S, Merz EH. Exophthalmos secondary to Periarteritis Nodosa. Am J Ophthalmol. 1963;56:204–208.
   PubMed Web of Science ®Google Scholar
• Ribeiro E, Cressend T, Duffau P, et al. Rituximab efficacy during a refractory Polyarteritis Nodosa Flare. Case Rep Med. 2009;2009:738293.
   PubMedGoogle Scholar
• Seri Y, Shoda H, Hanata N, et al. A case of refractory polyarteritis nodosa successfully treated with rituximab. Mod Rheumatol. 2015;1–3. doi:10.3109/14397595.2015.1014153; [Epub ahead of print]
   PubMedGoogle Scholar
• Campanilho-Marques R, Ramos F, Canhao H, et al. Remission induced by infliximab in a childhood polyarteritis nodosa refractory to conventional immunosuppression and rituximab. Joint Bone Spine. 2014;81(3):277–278.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc. 1980;55(3):146–155.
   PubMed Web of Science ®Google Scholar
• Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094–1100.
   PubMed Web of Science ®Google Scholar
• Akesbi J, Haroche J, LeHoang P, et al. Painful ophthalmoplegia as ocular manifestation in cytophagic histiocytic panniculitis associated with Churg Strauss syndrome. Orbit. 2009;28(1):63–65.
   PubMedGoogle Scholar
• Jordan N, Verma H, Ekbote A, et al. Dacryoadenitis and diffuse orbital inflammation: unusual first presentations of Churg-Strauss syndrome. Orbit. 2011;30(3):160–161.
   PubMedGoogle Scholar
• Pradeep TG, Prabhakaran VC, McNab A, et al. Diffuse bilateral orbital inflammation in Churg- Strauss syndrome. Ophthal Plast Reconstr Surg. 2010;26(1):57–59.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Ishii T, Harigae H. Churg-Strauss syndrome with exophthalmos and orbital bone destruction. Intern Med. 2010;49(14):1463–1464.
   PubMed Web of Science ®Google Scholar
• Jazayeri F, Pearson A. Orbital bruit in Churg-Strauss orbitopathy; a novel sign. Orbit. 2012;31(2):65–66.
   PubMedGoogle Scholar
• Takanashi T, Uchida S, Arita M, et al. Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome: report of two cases and review of the literature. Ophthalmology. 2001;108(6):1129–1133.
   PubMed Web of Science ®Google Scholar
• Baldini C, Talarico R, Della Rossa A, et al. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am. 2010;36(3):527–543.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2016;1–9. doi:10.1080/1744666X.2016.1205486. [Epub ahead of print]
   PubMedGoogle Scholar
• Bouomrani S, Farah A, Bouassida N, et al. [Orbital inflammatory pseudotumor with optic neuritis in Behcet’s disease]. J Fr Ophtalmol. 2012;35(6):439.e1-6.
   PubMed Web of Science ®Google Scholar
• Chebbi W, Jerbi S, Ammari W, et al. Orbital myositis in Behcet’s disease. Joint Bone Spine. 2014;81(3):264.
   PubMed Web of Science ®Google Scholar
• Hammami S, Yahia SB, Mahjoub S, et al. Orbital inflammation associated with Behcet’s disease. Clin Experiment Ophthalmol. 2006;34(2):188–190.
   PubMed Web of Science ®Google Scholar
• Roh JH, Koh SB, Kim JH. Orbital myositis in Behcet’s disease: A case report with MRI findings. Eur Neurol. 2006;56(1):44–45.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-alpha therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology. 2014;53(12):2223–2231.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behcets syndrome: effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45(3):369–373.
   PubMed Web of Science ®Google Scholar
• Ozguler Y, Hatemi G. Management of Behcet’s syndrome. Curr Opin Rheumatol. 2016;28(1):45–50.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: a multicenter study. Ophthalmology. 2014;121(10):1877–1884.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34(7):1293–1301.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Lopalco G, et al. New therapeutic solutions for Behcet’s syndrome. Expert Opin Investig Drugs. 2016;25(7):827–840.
   PubMed Web of Science ®Google Scholar
• Taylan A, Karakas B, Gulcu A, et al. Bilateral orbital pseudotumor in a patient with Takayasu arteritis: a case report and review of the literature. Rheumatol Int. 2016;36(5):743–746.
   PubMed Web of Science ®Google Scholar
• Reddi S, Vollbracht S. Giant cell arteritis associated with orbital pseudotumor. Headache. 2013;53(9):1488–1489.
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Krashin-Bichler I, Rosenblum M, et al. Giant cell arteritis presenting with bilateral orbital inflammatory disease and enhancing superficial temporal arteries. Pract Neurol. 2014;14(6):446–447.
   PubMedGoogle Scholar
• Nabili S, McCarey DW, Browne B, et al. A case of orbital myositis associated with rheumatoid arthritis. Ann Rheum Dis. 2002;61(10):938–939.
   PubMed Web of Science ®Google Scholar
• Panfilio CB, Hernandez-Cossio O, Hernandez-Fustes OJ. Orbital myositis and rheumatoid arthritis: case report. Arq Neuropsiquiatr. 2000;58(1):174–177.
   PubMed Web of Science ®Google Scholar
• Ibrahim I, Barton A, Ibrahim A, et al. Idiopathic orbital inflammation successfully treated using rituximab in a patient with rheumatoid arthritis. J Rheumatol. 2012;39(7):1485–1486.
   PubMed Web of Science ®Google Scholar
• Arthurs BP, Khalil MK, Chagnon F, et al. Orbital infarction and melting in a patient with systemic lupus erythematosus. Ophthalmology. 1999;106(12):2387–2390.
   PubMed Web of Science ®Google Scholar
• Burkhalter E. Unique presentation of systemic lupus erythematosus. Arthritis Rheum. 1973;16(3):428.
   PubMed Web of Science ®Google Scholar
• Feinfield RE, Hesse RJ, Rosenberg SA. Orbital inflammatory disease associated with systemic lupus erythematosus. South Med J. 1991;84(1):98–99.
   PubMed Web of Science ®Google Scholar
• Fonseca P, Manno RL, Miller NR. Bilateral sequential trochleitis as the presenting feature of systemic lupus erythematosus. J Neuroophthalmol. 2013;33(1):74–76.
   PubMed Web of Science ®Google Scholar
• Gray RE, Jenkins EA, Hall MA, et al. Recurrent acute proptosis in atypical systemic lupus erythematosus. Clin Rheumatol. 1989;8(4):528–532.
   PubMed Web of Science ®Google Scholar
• Grimson BS, Simons KB. Orbital inflammation, myositis, and systemic lupus erythematosus. Arch Ophthalmol. 1983;101(5):736–738.
   PubMedGoogle Scholar
• Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol. 1995;52(12):1145–1149.
   PubMedGoogle Scholar
• McDonald E, Marino C, Cimponeriu D. Painful ophthalmoplegia in a patient with SLE. Hosp Pract (Off Ed). 1992;27(11):41–44.
   PubMed Web of Science ®Google Scholar
• Ohsie LH, Murchison AP, Wojno TH. Lupus erythematosus profundus masquerading as idiopathic orbital inflammatory syndrome. Orbit. 2012;31(3):181–183.
   PubMedGoogle Scholar
• Sanchez IJ, Finger DR, Bradshaw DJ. Orbital inflammatory syndrome and systemic lupus erythematosus. J Clin Rheumatol. 1995;1(5):295–298.
   PubMedGoogle Scholar
• Serop S, Vianna RN, Claeys M, et al. Orbital myositis secondary to systemic lupus erythematosus. Acta Ophthalmol (Copenh). 1994;72(4):520–523.
   PubMed Web of Science ®Google Scholar
• Siebert S, Srinivasan U. Proptosis can be the presenting feature of systemic lupus erythematosus. Ann Rheum Dis. 2004;63(8):908–909.
   PubMed Web of Science ®Google Scholar
• Stavrou P, Murray PI, Batta K, et al. Acute ocular ischaemia and orbital inflammation associated with systemic lupus erythematosus. Br J Ophthalmol. 2002;86(4):474–475.
   PubMed Web of Science ®Google Scholar
• Holland KE, Steffes B, Nocton JJ, et al. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics. 2006;117(1):e132–6.
   PubMed Web of Science ®Google Scholar
• Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–1076.
   PubMed Web of Science ®Google Scholar
• Cline RA, Rootman J. Enophthalmos: a clinical review. Ophthalmology. 1984;91(3):229–237.
   PubMed Web of Science ®Google Scholar
• Fernando BS, Cannon PS, Tumuluri K, et al. Linear scleroderma as a rare cause of enophthalmos: a case report. J Med Case Rep. 2007;1:179.
   PubMedGoogle Scholar
• Gezer A, Tuncer S, Canturk S, et al. Bilateral acquired Brown syndrome in systemic scleroderma. J Aapos. 2005;9(2):195–197.
   PubMed Web of Science ®Google Scholar
• Kirkali PA, Kansu T, Sanac AS. Unilateral enophthalmos in systemic scleroderma. J Clin Neuroophthalmol. 1991;11(1):43–44.
   PubMedGoogle Scholar
• Olver J, Laidler P. Acquired Brown’s syndrome in a patient with combined lichen sclerosus et atrophicus and morphoea. Br J Ophthalmol. 1988;72(7):552–557.
   PubMed Web of Science ®Google Scholar
• Ramboer K, Demaerel P, Baert AL, et al. Linear scleroderma with orbital involvement: follow up and magnetic resonance imaging. Br J Ophthalmol. 1997;81(1):90–91.
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Koornneef L. Linear scleroderma associated with ptosis and motility disorders. Br J Ophthalmol. 1990;74(11):694–695.
   PubMed Web of Science ®Google Scholar
• Morris OC, Verity DH, Luthert PJ, et al. Orbital bone and soft tissue calcification in CREST syndrome. Clin Experiment Ophthalmol. 2010;38(5):534–536.
   PubMed Web of Science ®Google Scholar
• Kokotis P, Theodossiadis P, Bouros C, et al. Bilateral ocular myositis as a late complication of dermatomyositis. J Rheumatol. 2005;32(2):379–381.
   PubMed Web of Science ®Google Scholar
• Liu ZH, Wang XD. Acute-onset adult dermatomyositis presenting with erythroderma and diplopia. Clin Exp Dermatol. 2007;32(6):751–752.
   PubMed Web of Science ®Google Scholar
• Marasini B, Cossutta R, Massarotti M. Bilateral ocular myositis as a late complication of dermatomyositis. J Rheumatol. 2005;32(12):2498–2499. .
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kapaskelis A, Falagas ME. Periorbital and facial swelling due to dermatomyositis. Cmaj. 2007;176(11):1580–1581.
   PubMed Web of Science ®Google Scholar
• Sevigny GM, Mathes BM. Periorbital edema as the presenting sign of juvenile dermatomyositis. Pediatr Dermatol. 1999;16(1):43–45.
   PubMed Web of Science ®Google Scholar
• Taban M, Perry JD. Juvenile dermatomyositis presenting with periorbital edema. Ophthal Plast Reconstr Surg. 2006;22(5):393–395.
   PubMed Web of Science ®Google Scholar
• Fasano S, Alves SC, Isenberg DA. Current pharmacological treatment of idiopathic inflammatory myopathies. Expert Rev Clin Pharmacol. 2016;1–12. doi:10.1586/17512433.2016.1136561. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Statement on sarcoidosis. joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–755.
   PubMed Web of Science ®Google Scholar
• Smith JA, Foster CS. Sarcoidosis and its ocular manifestations. Int Ophthalmol Clin. 1996;36(1):109–125.
   PubMedGoogle Scholar
• Prabhakaran VC, Saeed P, Esmaeli B, et al. Orbital and adnexal sarcoidosis. Arch Ophthalmol. 2007;125(12):1657–1662.
   PubMedGoogle Scholar
• Mavrikakis I, Rootman J. Diverse clinical presentations of orbital sarcoid. Am J Ophthalmol. 2007;144(5):769–775.
   PubMed Web of Science ®Google Scholar
• Demirci H, Christianson MD. Orbital and adnexal involvement in sarcoidosis: analysis of clinical features and systemic disease in 30 cases. Am J Ophthalmol. 2011;151(6):1074–1080. .
   PubMed Web of Science ®Google Scholar
• Rabinowitz MP, Murchison AP. Orbital sarcoidosis treated with hydroxychloroquine. Orbit. 2011;30(1):13–15.
   PubMedGoogle Scholar
• Ajitsaria R, Dale R, Ferguson V, et al. psoriatic arthropathy and relapsing orbital myositis. Clin Exp Dermatol. 2001;26(3):274–275.
   PubMed Web of Science ®Google Scholar
• Ssi-Yan-Kai I, Pearson A. Orbital myositis and psoriatic arthritis. Can J Ophthalmol. 2012;47(6):e42–3.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4):1116–1122.
   PubMed Web of Science ®Google Scholar
• Bourikas LA, Roussomoustakaki M, Papadaki E, et al. A case of orbital myositis preceding the intestinal symptoms of Crohn’s disease. J Crohns Colitis. 2010;4(3):349–350.
   PubMed Web of Science ®Google Scholar
• Camfield PR, White M, Warner HA, et al. Orbital pseudotumor and Crohn disease. J Pediatr. 1982;101(1):157–158.
   PubMed Web of Science ®Google Scholar
• Cheng S, Vu P. Recurrent orbital myositis with radiological feature mimicking thyroid eye disease in a patient with Crohn’s disease. Orbit. 2009;28(6):368–370.
   PubMedGoogle Scholar
• Culver EL, Salmon JF, Frith P, et al. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn’s disease: case report and systematic literature review. J Crohns Colitis. 2008;2(4):337–342.
   PubMed Web of Science ®Google Scholar
• Durno CA, Ehrlich R, Taylor R, et al. Keeping an eye on Crohn’s disease: orbital myositis as the presenting symptom. Can J Gastroenterol. 1997;11(6):497–500.
   PubMed Web of Science ®Google Scholar
• Garrity JA, Coleman AW, Matteson EL, et al. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138(6):925–930.
   PubMed Web of Science ®Google Scholar
• Jain S, Gottlob I. Orbital myositis associated with ulcerative colitis. Am J Gastroenterol. 2001;96(12):3442–3444.
   PubMed Web of Science ®Google Scholar
• Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003;9(10):2300–2307.
   PubMed Web of Science ®Google Scholar
• Leibovitch I, Galanopoulos A, Selva D. Suppurative granulomatous myositis of an extra-ocular muscle in Crohn’s disease. Am J Gastroenterol. 2005;100(9):2136–2137.
   PubMed Web of Science ®Google Scholar
• Maalouf T, Angioi K, George JL. Recurrent orbital myositis and Crohn’s disease. Orbit. 2001;20(1):75–80.
   PubMedGoogle Scholar
• Macarez R, Bazin S, Weber F, et al. [Orbital myositis associated with ulcerative colitis]. J Fr Ophtalmol. 2005;28(6):610–613.
   PubMed Web of Science ®Google Scholar
• Pimentel R, Lago P, Pedroto I. Recurrent orbital myositis as an extra-intestinal manifestation of Crohn’s disease. J Crohns Colitis. 2012;6(9):958–959.
   PubMed Web of Science ®Google Scholar
• Ramalho J, Castillo M. Imaging of orbital myositis in Crohn’s disease. Clin Imaging. 2008;32(3):227–229.
   PubMed Web of Science ®Google Scholar
• Smith JW. Orbital pseudotumor and Crohn’s disease. Am J Gastroenterol. 1992;87(3):405–406.
   PubMed Web of Science ®Google Scholar
• Squires RH Jr., Zwiener RJ, Kennedy RH. Orbital myositis and Crohn’s disease. J Pediatr Gastroenterol Nutr. 1992;15(4):448–451.
   PubMed Web of Science ®Google Scholar
• Verbraeken H, Ryckaert S, Demets W. Pseudotumor of the orbit and Crohn’s disease. Bull Soc Belge Ophtalmol. 1984;210:65–72.
   PubMedGoogle Scholar
• Weinstein JM, Koch K, Lane S. Orbital pseudotumor in Crohn’s colitis. Ann Ophthalmol. 1984;16(3):275–278.
   PubMedGoogle Scholar
• Young RS, Hodes BL, Cruse RP, et al. Orbital pseudotumor and Crohn disease. J Pediatr. 1981;99(2):250–252.
   PubMed Web of Science ®Google Scholar
• Felekis T, Katsanos K, Christodoulou D, et al. Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn’s disease. J Crohns Colitis. 2009;3(3):212–214.
   PubMed Web of Science ®Google Scholar
• Ouakaa-Kchaou A, Gargouri D, Trojet S, et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn’s disease. J Crohns Colitis. 2009;3(2):131–133.
   PubMed Web of Science ®Google Scholar
• Strong BY, Erny BC, Herzenberg H, et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med. 2004;140(8):W34.
   PubMedGoogle Scholar
• Hejazi R, Colombel JF, Peyrin-Biroulet L. Retrobulbar optic neuritis during infliximab treatment for ulcerative colitis. Gastroenterol Clin Biol. 2008;32(2):162–163.
   PubMedGoogle Scholar
• Mumoli N, Niccoli G, Scazzeri F, et al. Infliximab-induced retrobulbar optic neuritis. Qjm. 2007;100(8):531.
   PubMed Web of Science ®Google Scholar
• Katsanos A, Asproudis I, Katsanos KH, et al. Orbital and optic nerve complications of inflammatory bowel disease. J Crohns Colitis. 2013;7(9):683–693.
   PubMed Web of Science ®Google Scholar
• Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol. 1988;5(4):346–364.
   PubMed Web of Science ®Google Scholar
• Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3(9):1202–1216.
   PubMed Web of Science ®Google Scholar
• Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670–683.
   PubMed Web of Science ®Google Scholar
• Park KS, Choi YJ, Song KS. Hyaline-vascular type Castleman’s disease involving both orbits. Acta Ophthalmol Scand. 2002;80(5):537–539.
   PubMedGoogle Scholar
• Venizelos I, Papathomas TG, Papathanasiou M, et al. Orbital involvement in Castleman disease. Surv Ophthalmol. 2010;55(3):247–255.
   PubMed Web of Science ®Google Scholar
• Jones NW, Fountain TR, Thakral B, et al. Castleman’s disease in the orbit of a 17-year-old girl: a case report. Ophthal Plast Reconstr Surg. 2014;30(1):e17–20.
   PubMed Web of Science ®Google Scholar
• Koppens JM, Pon JA, Allen J, et al. Castleman’s disease of the lacrimal gland. Clin Experiment Ophthalmol. 2004;32(1):108–110.
   PubMed Web of Science ®Google Scholar
• Snead MP, James JN, Snead DR, et al. Orbital lymphomas and Castleman’s disease. Eye (Lond). 1993;7(Pt 1):84–88.
   PubMed Web of Science ®Google Scholar
• Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129(1):3–17.
   PubMed Web of Science ®Google Scholar
• Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virus-related Castleman’s disease with interferon-alpha. Clin Infect Dis. 2000;31(2):602–604.
   PubMed Web of Science ®Google Scholar
• Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman’s disease. Int J STD AIDS. 2003;14(1):61–62.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–676.
   PubMed Web of Science ®Google Scholar
• Alyahya GA, Prause JU, Heegaard S. Castleman’s disease in the orbit. A 20-year follow-up. Acta Ophthalmol Scand. 2002;80(5):540–542.
   PubMedGoogle Scholar
• Robinson D Jr., Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol. 2014;165(1):39–48.
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Ko CW, Nie L, et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res. 2015;21(5):950–954.
   PubMed Web of Science ®Google Scholar
• Azari AA, Kanavi MR, Lucarelli M, et al. Angiolymphoid hyperplasia with eosinophilia of the orbit and ocular adnexa: report of 5 cases. JAMA Ophthalmol. 2014;132(5):633–636.
   PubMed Web of Science ®Google Scholar
• Buggage RR, Spraul CW, Wojno TH, et al. Kimura disease of the orbit and ocular adnexa. Surv Ophthalmol. 1999;44(1):79–91.
   PubMed Web of Science ®Google Scholar
• Kapoor NS, O’Neill JP, Katabi N, et al. Kimura disease: diagnostic challenges and clinical management. Am J Otolaryngol. 2012;33(2):259–262.
   PubMed Web of Science ®Google Scholar
• Baker MS, Avery RB, Johnson CR, et al. Methotrexate as an alternative treatment for orbital angiolymphoid hyperplasia with eosinophilia. Orbit. 2012;31(5):324–326.
   PubMedGoogle Scholar
• Bangal S, Chitgopekar R, Gupta A, et al. Orbital extension of supraorbital angiolymphoid hyperplasia with eosinophilia. Australas Med J. 2011;4(3):111–113.
   PubMedGoogle Scholar
• Cunniffe G, Alonso T, Dinares C, et al. Angiolymphoid hyperplasia with eosinophilia of the eyelid and orbit: the Western cousin of Kimura’s disease? Int Ophthalmol. 2014;34(1):107–110.
   PubMed Web of Science ®Google Scholar
• Fernandes BF, Al-Mujaini A, Petrogiannis-Haliotis T, et al. Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia) of the orbit: a case report. J Med Case Rep. 2007;1:30.
   PubMedGoogle Scholar
• Francis IC, Kappagoda MB, Smith J, et al. Kimura’s disease of the orbit. Ophthal Plast Reconstr Surg. 1988;4(4):235–239.
   PubMedGoogle Scholar
• Kanazawa S, Gong H, Kitaoka T, et al. Eosinophilic granuloma (Kimura’s disease) of the orbit: a case report. Graefes Arch Clin Exp Ophthalmol. 1999;237(6):518–521.
   PubMed Web of Science ®Google Scholar
• Kodama T, Kawamoto K. Kimura’s disease of the lacrimal gland. Acta Ophthalmol Scand. 1998;76(3):374–377.
   PubMedGoogle Scholar
• Krema H, El-Bolkainy N. A stepwise multimodality treatment of diffuse angiolymphoid hyperplasia of the orbit. Orbit. 2014;33(1):75–77.
   PubMedGoogle Scholar
• Kubo T, Hosokawa K, Kamiji T. Angiolymphoid hyperplasia with eosinophilia of the orbit. Ann Plast Surg. 2000;44(6):683–684.
   PubMed Web of Science ®Google Scholar
• Monzen Y, Kiya K, Nishisaka T. Kimura’s disease of the orbit successfully treated with radiotherapy alone: a case report. Case Rep Ophthalmol. 2014;5(1):87–91.
   PubMedGoogle Scholar
• Sanchez-Acosta A, Moreno-Arredondo D, Rubio-Solornio RI, et al. Angiolymphoid hyperplasia with eosinophilia of the lacrimal gland: a case report. Orbit. 2008;27(3):195–198.
   PubMedGoogle Scholar
• Sanchez-Orgaz M, Insausti-Garcia A, Gregorio LY, et al. Epithelioid hemangioma of the orbit or angiolymphoid hyperplasia with eosinophilia. Ophthal Plast Reconstr Surg. 2014;30(3):e70–2.
   PubMed Web of Science ®Google Scholar
• Elias MK, Mateen FJ, Weiler CR. The Melkersson-Rosenthal syndrome: a retrospective study of biopsied cases. J Neurol. 2013;260(1):138–143.
   PubMed Web of Science ®Google Scholar
• Hornstein OP. Melkersson-Rosenthal syndrome. A neuro-muco-cutaneous disease of complex origin. Curr Probl Dermatol. 1973;5:117–156.
   PubMedGoogle Scholar
• Shapiro M, Peters S, Spinelli HM. Melkersson-Rosenthal syndrome in the periocular area: a review of the literature and case report. Ann Plast Surg. 2003;50(6):644–648.
   PubMed Web of Science ®Google Scholar
• Kajal B, Harvey J, Alowami S. Melkerrson-Rosenthal Syndrome, a rare case report of chronic eyelid swelling. Diagn Pathol. 2013;8:188.
   PubMed Web of Science ®Google Scholar
• McNab AA. Re ‘Isolated eyelid edema in Melkersson-Rosenthal syndrome: a case series’. Eye (Lond). 2012;26(6):893. .
   PubMed Web of Science ®Google Scholar
• Rawlings NG, Valenzuela AA, Allen LH, et al. Isolated eyelid edema in Melkersson-Rosenthal syndrome: a case series. Eye (Lond). 2012;26(1):163–166.
   PubMed Web of Science ®Google Scholar
• Sabet-Peyman EJ, Woodward JA. A case series of patients diagnosed with orofacial granulomatosis presenting primarily with dense infiltrates and severe periorbital edema. Ophthal Plast Reconstr Surg. 2014;30(6):e151–5.
   PubMed Web of Science ®Google Scholar
• Wong BJ, Hong BK, Samrao D, et al. A 49-year-old man with unilateral, nontender left eyelid swelling. Digit J Ophthalmol. 2014;20(1):15–19.
   PubMedGoogle Scholar
• Feng S, Yin J, Li J, et al. Melkersson-Rosenthal syndrome: a retrospective study of 44 patients. Acta Otolaryngol. 2014;134(9):977–981.
   PubMed Web of Science ®Google Scholar
• Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7(1):19–73.
   PubMed Web of Science ®Google Scholar
• Foucar E, Rosai J, Dorfman RF. The ophthalmologic manifestations of sinus histiocytosis with massive lymphadenopathy. Am J Ophthalmol. 1979;87(3):354–367.
   PubMed Web of Science ®Google Scholar
• McClellan SF, Ainbinder DJ. Orbital Rosai-Dorfman disease: a literature review. Orbit. 2013;32(5):341–346.
   PubMedGoogle Scholar
• Mohadjer Y, Holds JB, Rootman J, et al. The spectrum of orbital Rosai-Dorfman disease. Ophthal Plast Reconstr Surg. 2006;22(3):163–168.
   PubMed Web of Science ®Google Scholar
• Prabhakaran VC, Bhatnagar A, Sandilla J, et al. Orbital and adnexal Rosai-Dorfman disease. Orbit. 2008;27(5):356–362.
   PubMedGoogle Scholar
• Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol. 2002;69(1):67–71.
   PubMed Web of Science ®Google Scholar
• Tan JJ, Narang S, Purewal B, et al. Extranodal Rosai-Dorfman disease of the orbit: clinical features of 8 cases. Ophthal Plast Reconstr Surg. 2015. doi:10.1097/IOP.0000000000000589. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Alqanatish JT, Houghton K, Bond M, et al. Rituximab treatment in a child with rosai-dorfman disease and systemic lupus erythematosus. J Rheumatol. 2010;37(8):1783–1784.
   PubMed Web of Science ®Google Scholar
• Cooper SL, Chavis PS, Fortney JA, et al. A case of orbital Rosai-Dorfman disease responding to radiotherapy. J Pediatr Hematol Oncol. 2008;30(10):744–748.
   PubMed Web of Science ®Google Scholar
• Reddy A, Beigi B, Linardos E. Rosai-Dorfman syndrome affecting the lacrimal gland. Orbit. 2001;20(3):239–242.
   PubMedGoogle Scholar
• Vemuganti GK, Naik MN, Honavar SG. Rosai dorfman disease of the orbit. J Hematol Oncol. 2008;1:7.
   PubMed Web of Science ®Google Scholar
• Yilmaz S, Ture M, Maden A, et al. Extranodal Rosai-Dorfman disease with bilateral orbital involvement: report of a case treated with systemic steroid alone. Clin Ophthalmol. 2008;2(2):479–481.
   PubMedGoogle Scholar
• Goldberg S, Mahadevia P, Lipton M, et al. Sinus histiocytosis with massive lymphadenopathy involving the orbit: reversal of compressive optic neuropathy after chemotherapy. J Neuroophthalmol. 1998;18(4):270–275.
   PubMed Web of Science ®Google Scholar